
    
      The design of the study is an open label, multicentre, single arm trial with subjects with
      moderate to heavily exuding chronic and acute wounds consisting of pressure ulcers, leg
      ulcers, diabetic leg and foot ulcers, surgical wounds first degree superficial and partial
      thickness burns. The performance data from this study will support clinically meaningful
      rates of successful improvement in the signs and symptoms of infection, without refection
      during 6- week treatment and follow up period.
    
  